Corticobasal degeneration: Selected developments

Movement Disorders

Volumn 18, Issue SUPPL. 6, 2003, Pages

  Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Corticobasal degeneration; Corticobasal ganglionic degeneration; Tauopathy

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN; CHOLINESTERASE INHIBITOR; CLONAZEPAM; LEVODOPA; VALPROIC ACID;

BRAIN INJURY; BRAIN NERVE CELL; CLINICAL FEATURE; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DYSKINESIA; DYSTONIA; GENETIC DISORDER; GLIA CELL; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; MOTOR NEURON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RETROSPECTIVE STUDY; REVIEW; TAUOPATHY;

EID: 0141725653     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10563     Document Type: Review

References (47)

1. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20-33.
2. Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40: 1203-1212.
3. Gibb WRG, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989;112:1171-1192.
4. Watts RL, Williams RS, Growdon JD, Young RR, Haley EC, Beal MF. Corticobasal ganglionic degeneration [abstract]. Neurology 1985;35(Suppl. 1):178.
5. Constantinidis J, Richard J, Tissot R. Pick's disease: histological and clinical correlations. Eur Neurol 1974;11:208-217.
6. Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders; 1994. p 877-894.
7. Kumar R, Bergeron C, Pollanen M, Lang AE. Cortical-basal ganglionic degeneration. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998. p 297-316.
8. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61: 935-946.
9. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
10. Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53:795-800.
11. Boeve B, Parisi J, Dickson D, Maraganore D, Ahlskog JE, Graff-Radford N, et al. Demographic and clinical findings in 20 cases of pathologically-diagnosed corticobasal degeneration. Mov Disord 2003;15(Suppl. 3):228.
12. Cordato NJ, Halliday GM, McCann H, Davies L, Williamson P, Fulham M, et al. Corticobasal syndrome with tau pathology. Mov Disord 2001;16:656-667.
13. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969-1974.
14. Lang AE. Cortical-basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia." J Neurol Neurosurg Psychiatry 1992;55:1101.
15. Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001;16:252-257.
16. Peigneux P, Salmon E, Garraux G, Laureys S, Willems S, Dujardin K, et al. Neural and cognitive bases of upper limb apraxia in corticobasal degeneration. Neurology 2001;57:1259-1268.
17. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995;45:1477-1483.
18. Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001;56:957-963.
19. Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994;57:455-459.
20. Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65:717-721.
21. Massman PJ, Kreiter KT. Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: differentiation from Alzheimer's disease. Neurology 1996;46:720-726.
22. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991;114:541-556.
23. Blin J, Vidailhet M-J, Pillon B, Dubois B, Feve J-R, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992;7:348-354.
24. Giménez-Roldán S, Mateo D, Benito C, Grandas F, Pérez-Gilabert Y. Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. J Neural Transm 1994;98(Suppl. 42):79-90.
25. Hirono N, Ishii K, Sasaki M, Kitagaki H, Hashimoto M, Imamura T, et al. Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration. Dementia 2000;11:139-146.
26. Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M. Cerebral blood flow in corticobasal degeneration and progressive supranuclear palsy. Alzheimer Dis Assoc Disord 2000;14:46-52.
27. Brooks DJ. Functional imaging studies in corticobasal degeneration. Adv Neurol 2000;82:209-215.
28. Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 2002; 199:67-71.
29. Oide T, Ohara S, Yazawa M, Inoue K, Itoh N, Tokuda T, et al. Progressive supranuclear palsy with asymmetric tau pathology presenting with unilateral limb dystonia. Acta Neuropathol (Berl) 2002;104:209-214.
30. Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997;56:726-734.
31. Togo T, Dickson DW. Ballooned neurons in progressive supranuclear palsy are usually due to concurrent argyrophilic grain disease. Acta Neuropathol (Berl) 2002;104:53-56.
32. Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 2001;101:167-173.
33. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706.
34. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 2001;60:647-657.
35. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-233.
36. Arai T, Ikeda K, Akiyama H, Tsuchiya K, Yagishita S, Takamatsu J. Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy. Neuroreport 2001;12:935-938.
37. Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000;15:340-343.
38. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001;16:907-913.
39. Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JP, Beal MF. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 1999;73:881-884.
40. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001;24:347-352.
41. Park LCH, Albers DS, Xu H, Lindsay JG, Beal MF, Gibson GE. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J Neurosci Res 2001;66:1028-1034.
42. Albers DS, Swerdlow RH, Manfredi G, Gajewski C, Yang LC, Parker WD Jr, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 2001;168:196-198.
43. Chirichigno JW, Manfredi G, Beal MF, Albers DS. Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Res 2002;951:31-35.
44. Fitzmaurice PS, Bamsey CL, Ang L, Guttman M, Rajput AH, Furukawa Y, et al. Brain aconitase activity is not decreased in progressive supranuclear palsy. Neurology 2002;59:137-138.
45. Cantuti-Castelvetri I, Keller-McGandy CE, Albers DS, Beal MF, Vonsattel JP, Standaert DG, et al. Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res 2002;930:170-181.
46. Hartzler AW, Zhu XW, Siedlak SL, Castellani RJ, Avilá J, Perry G, et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging 2002;23: 855-859.
47. Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry, G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 1995;696:268-271.